Cancer drug safety tracked in ongoing rollover trial
NCT ID NCT06788509
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-75348780, safimaltib, and ibrutinib
What this could lead to
If successful, this study will confirm the long-term safety of these cancer drugs, supporting their continued use in patients who benefit.
What could go wrong
This is an early-phase rollover study focused on safety, not efficacy. It enrolls only patients already benefiting, so results may not apply to all. Side effects remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aidport Sp z o o
Skorzewo, 60-185, Poland
-
Alexandra Hospital
Athens, 115 28, Greece
-
Arensia Exploratory Medicine
Tbilisi, Postal code 0112, Georgia
-
Arensia Exploratory Medicine
Chisinau, 2025, Moldova
-
CHU Nantes
Nantes, 44093, France
-
Chang Kung Memorial Hospital
Kaohsiung City, 833, Taiwan
-
China Medical University Hospital
Taichung, 404327, Taiwan
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Hadassah University Hospita Ein Kerem
Jerusalem, 9112001, Israel
-
Hopital Claude Huriez
Lille, 59000, France
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp Univ Vall D Hebron 1
Barcelona, 08035, Spain
-
Hosp. Clinic de Barcelona
Barcelona, 08036, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Medical Center of Limited Liability Company Arensia Exploratory Medicine
Kyiv, 01135, Ukraine
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
National Hospital Organization Nagoya Medical Center
Nagoya, 460-0001, Japan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Pratia MCM Krakow
Krakow, 30-727, Poland
-
Rambam Med.Center - Hematology Institute
Haifa, 3109601, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
St Bartholomews Hospital
London, EC1A 7BE, United Kingdom
-
The Cancer Institute Hospital of JFCR
Tokyo, 135 8550, Japan
-
University Hospitals Of Leicester Nhs Trust
Leicester, Le1 5ww, United Kingdom
-
University Hospitals Plymouth NHS Trust
Plymouth, PL6 8DH, United Kingdom
-
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, 80 214, Poland